



INNOVATION IN EDUCATION



This material is the exclusive property of the Avantyo Institute of Clinical Research.

Any reproduction or distribution of this content is strictly prohibited without prior authorization and may result in legal action!

Status Quo and Future Prospects -National Strategy for Developing Clinical Trials in Romania

Dr. George Tanaseanu / President ACCSCR

08 Nov 2024 Bucharest




The Joy Ride is over...


- · After years of easy money and heady growth, funding is slim, and stocks are down
- Layoffs and shutdowns hit biotech industry in U-turn
- The global clinical trial ecosystem is evolving; Europe's share is declining, while Asia is emerging as a major location for new clinical trial starts
- * In oncology and neurology, the EEA has experienced contrasting trends to US (CAGR -22% since 2018 and -42% respectively)
- * Europe's share of Cell and Gene Therapy trials has decreased since 2013, whilst China has experienced rapid growth in the last decade
- * The number of both commercial and non-commercial paediatric trials are declining in the EEA, against a backdrop of global limited growth (CAGR -4% / -11% since 2013)
- * In rare diseases, trial starts in the EEA are declining, whereas globally, trial starts remained broadly flat in 2023 compared to 2019 (CAGR -4% / -12% since 2013)

 ACCSCR


DE STÚDII CLINICE DIN ROMÂNIA

































Drug Discovery is difficult - A Shift in Scientific Paradigm

- Nascent industry "AI-Designed Drugs" Generative AI and Digital Twins are Accelerating Innovation
- Precision Medicine and Personalized Therapies
- Expansion of RNA and Gene-Based Therapies
- Data Integration and Sharing via Cloud Technologies
- Increased Emphasis on Rare Diseases and Orphan Drugs
- Adoption of Advanced Biomarkers and Digital Health Technologies
- Patient-Centric Trial Designs and Decentralized Clinical Trials

